Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Drug Profile

Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Alternative Names: Piperaquine + fosmidomycin combination therapy - Jomaa Pharma/Medicines for Malaria Venture

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Jomaa Pharma; Justus Liebig University
  • Developer Jomaa Pharma
  • Class Organophosphorus compounds; Phosphonic acids; Quinolones; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 14 Nov 2016 Jomaa Pharma completes a phase IIa trial in Malaria (In children, In adults) in Gabon
  • 05 Aug 2016 Jomaa Pharma plans a dose-optimisation clinical trial for Malaria (In children) in sub-Saharan Africa
  • 01 Mar 2014 Phase-IIa clinical trials in Malaria (In children, In adults) in Gabon (PO) (NCT02198807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top